Chris Schott
Stock Analyst at JP Morgan
(4.07)
# 484
Out of 5,165 analysts
155
Total ratings
62.62%
Success rate
8%
Average return
Main Sectors:
Stocks Rated by Chris Schott
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| JNJ Johnson & Johnson | Maintains: Neutral | $225 → $250 | $243.19 | +2.80% | 1 | Mar 5, 2026 | |
| ELAN Elanco Animal Health | Maintains: Overweight | $24 → $28 | $23.40 | +19.66% | 5 | Feb 19, 2026 | |
| LLY Eli Lilly and Company | Maintains: Overweight | $1,150 → $1,300 | $989.12 | +31.43% | 24 | Feb 5, 2026 | |
| REGN Regeneron Pharmaceuticals | Maintains: Overweight | $850 → $950 | $756.91 | +25.51% | 9 | Feb 2, 2026 | |
| TEVA Teva Pharmaceutical Industries | Maintains: Overweight | $28 → $35 | $29.46 | +18.81% | 20 | Dec 16, 2025 | |
| PRGO Perrigo Company | Maintains: Neutral | $20 → $18 | $9.72 | +85.19% | 14 | Dec 15, 2025 | |
| OGN Organon & Co. | Maintains: Underweight | $14 → $12 | $6.34 | +89.27% | 3 | Nov 11, 2025 | |
| ZTS Zoetis | Maintains: Overweight | $230 → $200 | $118.15 | +69.28% | 3 | Nov 5, 2025 | |
| IDXX IDEXX Laboratories | Maintains: Overweight | $675 → $775 | $586.37 | +32.17% | 9 | Nov 4, 2025 | |
| ABBV AbbVie | Maintains: Overweight | $250 → $260 | $221.45 | +17.41% | 4 | Nov 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $145 → $150 | $145.21 | +3.30% | 8 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $12 → $14 | $11.94 | +17.25% | 3 | Sep 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $185 → $175 | $183.26 | -4.51% | 4 | May 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $45 → $42 | $46.10 | -8.89% | 4 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | $270 | $366.25 | -26.28% | 1 | Oct 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $36 → $34 | $26.61 | +27.77% | 10 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $120 → $125 | $115.43 | +8.29% | 7 | Feb 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $13 → $14 | $13.51 | +3.63% | 2 | Nov 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $13 → $11 | $1.66 | +562.65% | 4 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $5.03 | - | 4 | Jul 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $74 → $78 | $59.71 | +30.63% | 7 | Oct 16, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $700 → $950 | $0.27 | +356,506.61% | 4 | May 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $2.17 | - | 2 | May 19, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $45 → $50 | $22.69 | +120.36% | 3 | Nov 2, 2018 |
Johnson & Johnson
Mar 5, 2026
Maintains: Neutral
Price Target: $225 → $250
Current: $243.19
Upside: +2.80%
Elanco Animal Health
Feb 19, 2026
Maintains: Overweight
Price Target: $24 → $28
Current: $23.40
Upside: +19.66%
Eli Lilly and Company
Feb 5, 2026
Maintains: Overweight
Price Target: $1,150 → $1,300
Current: $989.12
Upside: +31.43%
Regeneron Pharmaceuticals
Feb 2, 2026
Maintains: Overweight
Price Target: $850 → $950
Current: $756.91
Upside: +25.51%
Teva Pharmaceutical Industries
Dec 16, 2025
Maintains: Overweight
Price Target: $28 → $35
Current: $29.46
Upside: +18.81%
Perrigo Company
Dec 15, 2025
Maintains: Neutral
Price Target: $20 → $18
Current: $9.72
Upside: +85.19%
Organon & Co.
Nov 11, 2025
Maintains: Underweight
Price Target: $14 → $12
Current: $6.34
Upside: +89.27%
Zoetis
Nov 5, 2025
Maintains: Overweight
Price Target: $230 → $200
Current: $118.15
Upside: +69.28%
IDEXX Laboratories
Nov 4, 2025
Maintains: Overweight
Price Target: $675 → $775
Current: $586.37
Upside: +32.17%
AbbVie
Nov 3, 2025
Maintains: Overweight
Price Target: $250 → $260
Current: $221.45
Upside: +17.41%
Oct 31, 2025
Maintains: Overweight
Price Target: $145 → $150
Current: $145.21
Upside: +3.30%
Sep 16, 2025
Maintains: Overweight
Price Target: $12 → $14
Current: $11.94
Upside: +17.25%
May 5, 2025
Maintains: Neutral
Price Target: $185 → $175
Current: $183.26
Upside: -4.51%
Feb 20, 2024
Maintains: Overweight
Price Target: $45 → $42
Current: $46.10
Upside: -8.89%
Oct 20, 2023
Reinstates: Neutral
Price Target: $270
Current: $366.25
Upside: -26.28%
Oct 16, 2023
Maintains: Neutral
Price Target: $36 → $34
Current: $26.61
Upside: +27.77%
Feb 23, 2023
Maintains: Overweight
Price Target: $120 → $125
Current: $115.43
Upside: +8.29%
Nov 15, 2022
Maintains: Neutral
Price Target: $13 → $14
Current: $13.51
Upside: +3.63%
Nov 14, 2022
Maintains: Neutral
Price Target: $13 → $11
Current: $1.66
Upside: +562.65%
Jul 29, 2022
Downgrades: Neutral
Price Target: n/a
Current: $5.03
Upside: -
Oct 16, 2020
Maintains: Overweight
Price Target: $74 → $78
Current: $59.71
Upside: +30.63%
May 27, 2020
Maintains: Overweight
Price Target: $700 → $950
Current: $0.27
Upside: +356,506.61%
May 19, 2020
Downgrades: Neutral
Price Target: n/a
Current: $2.17
Upside: -
Nov 2, 2018
Maintains: Neutral
Price Target: $45 → $50
Current: $22.69
Upside: +120.36%